Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Genetically at-risk healthy people show similar immune issues as those with Pemphigus vulgaris or Alopecia areata.

A mycobacterial protein shares a similar region with a human skin protein, possibly affecting skin diseases.

Certain microRNAs may help treat alopecia areata by targeting immune pathways.

iNKT cells can help prevent and treat alopecia areata by promoting hair regrowth.

Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Atopic dermatitis affects the appearance of skin reactions, making certain features more common and improving diagnostic accuracy with dermoscopy.

UVB exposure in human skin causes macrophages to produce more IL-10 and less IL-12, leading to immunosuppression.

Restoring hair follicle immune privilege may help treat alopecia areata.

Skin reactions from cancer treatments might predict how well the treatments work.

The study suggested certain immune cells might cause alopecia areata, but it was retracted.

People with alopecia areata have fewer IL-10 producing immune cells, which might contribute to the condition.

COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.

Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.

Immunological treatment improved both neuropathy and alopecia.

Skin reactions are a common reason for emergency visits due to drug allergies, with some severe cases needing intensive care.

Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.

Topical immunotherapy for alopecia areata may work by creating immune cell clusters in the skin.

Hair follicles in nonsegmental vitiligo are better protected from immune attacks than in alopecia areata.

ILC1-like cells can cause alopecia areata by affecting hair follicles.

Alopecia areata is an autoimmune disease causing hair loss, treatable with immune-modulating drugs, and linked to genetics.

The document concludes that computational models are useful for understanding immune responses and could improve cancer immunotherapy.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Immune therapy for cancer can cause rare hair loss but doesn't stop treatment success.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Homeopathy might help manage autoimmune diseases.

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.